Radiotherapy for Oligometastatic Prostate Cancer

Completed · Not applicable

Conditions studied: Oligometastatic Prostate Cancer

In brief

The purpose of this phase II study is to evaluate the outcomes of patients treated with an investigational radiation regimen using stereotactic radiotherapy for oligometastatic prostate cancer and to establish efficacy (producing a desired result or effect) and safety in this setting.

Key facts

Study ID

NCT01859221

Run by

University of Florida

People needed

39

Starts

2013-05-01

Expected to finish

2022-09-13

Last updated by the study team

2022-09-14

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients with metastatic cancer of the prostate,
• Patients may have received prior surgery,
• Prior radiation therapy, androgen deprivation therapy (ADT), immunotherapy, bone metastasis directed therapy, or chemotherapy for prostate cancer.

You may not qualify if…

• End-stage heart disease,
• End-stage liver disease,
• End-stage renal disease,
• End stage pulmonary disease
• Current brain or central nervous system metastasis.

Where it is running

• University of Florida Proton Therapy Institute — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.